Clinical Trials Logo
  1. Home
  2. Peanut Allergy
  3. NCT02821286
  4. Details
NCT02821286 Clinical Trial

Identification of Anaphylactogenic Antibodies in Peanut Allergy

Peanut Allergy Clinical Trial

Official title:
Identification of Anaphylactogenic Antibodies in the Blood of Peanut Allergic Patients

Clinical Trial Details — Status: Enrolling by invitation

Administrative data
NCT number NCT02821286
Other study ID # UZH
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date June 2016
Est. completion date December 2025

Study information
Verified date December 2023
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.

Description:

- Characterization of patient samples reactivity (sera obtained from blood) against major peanut allergens. - Isolation of antibody-producing B cells. - Molecular cloning of peanut-specific antibodies from antibody gene sequences obtained from B cells. - Biophysical and functional characterization of isolated antibodies

Recruitment information / eligibility
Status Enrolling by invitation
Enrollment 100
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: - Participants have a described clinical history of peanut allergy and/or are sensitized to peanut allergens (as evidenced by positive skin prick test and allergen-specific IgE testing) - Male and female subjects older than 3 years - Written informed consent Exclusion Criteria: - age below three years - patients suffering from any disease where blood withdrawals might impact the patients' health status such as known anemia.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Observational study
Blood sampling

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
University of Zurich University Children's Hospital, Zurich

Outcome
Type Measure Description Time frame Safety issue
Primary Analysis and profiling of specific antibodies against major peanut allergens in samples derived from peanut allergic patients. June 2016 to May 2018
See also
  Status Clinical Trial Phase
Recruiting NCT05667610 - Immune-supportive Diet and Gut Permeability in Allergic Children N/A
Recruiting NCT05440643 - Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Phase 1
Terminated NCT03849079 - Validation of the HYPONUT Product N/A
Completed NCT02979600 - Clinical and Biological Efficacy of Peanut Oral Immunotherapy N/A
Completed NCT01955109 - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Phase 2
Completed NCT01950533 - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Recruiting NCT04415593 - High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety N/A
Active, not recruiting NCT04511494 - Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Active, not recruiting NCT04881773 - Oral Low Doses Tolerance INduction Study for Peanuts
Completed NCT03682770 - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Phase 2
Terminated NCT03703791 - Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents Phase 3
Completed NCT02916446 - Safety Study of Viaskin Peanut to Treat Peanut Allergy Phase 3
Active, not recruiting NCT02402231 - Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Phase 2
Completed NCT03337542 - AR101 Real-World Open-Label Extension Study Phase 3
Recruiting NCT05476497 - Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects Phase 1
Completed NCT03648320 - The Grown Up Peanut Immunotherapy Study N/A
Completed NCT03292484 - Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Phase 3
Completed NCT03852342 - Reactive Doses and Times During Oral Food Challenge to Peanut
Recruiting NCT05138757 - Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Phase 1/Phase 2